Peri-implantitis is an infection around a dental implant that destroys the surrounding bone and can cost the patient the implant. The EIC project's report says that after nine years 60% of implants show bone loss of about 30%. Freiburger Medizintechnik, a Freiburg company, developed AmbiJet, which uses cold atmospheric plasma, an electrically charged gas, to kill bacteria and break up the biofilm on an infected implant without removing the crown.
The European Innovation Council granted €1,389,062 towards a €1.98 million project that ran from October 2022 to September 2025. According to the CORDIS report, the team built a base station and applicators "that can be mass-manufactured" and "passed all necessary tests required by the European regulatory framework, incl. the Medical Device Regulation". In 2026 the company's website says "the countdown to market approval" has begun, and an exploratory clinical study of about 26 patients started in February 2026.
Company file
- Legal entity
- Freiburger Medizintechnik GmbH, HRB 718793, Freiburg
- Purpose
- Invention and development of medical devices
- Product
- AmbiJet cold plasma system: base unit and single-use applicators
- Other public funding
- German Dentalplas grant, €741,943
- EIC project
- AmbiJet, 1 Oct 2022 to 30 Sep 2025
- EIC funding
- Grant first; no EIC Fund investment announced
Where Freiburger Medizintechnik Stands Today
The company's recent news consists of appearances at dental congresses, including the IADR meeting in San Diego in March 2026 and the EAO congress in Monaco in 2025, and a 2025 publication on removing mature oral biofilm. The ClinicalTrials.gov record, first posted in July 2026, describes an exploratory study of AmbiJet in peri-implantitis and peri-implant mucositis, recruiting about 26 people with completion estimated in November 2026. The commercial register shows share capital raised from €25,000 to €33,088 by August 2025.
The Technology: Plasma at the Gum Line
The company reports a "5-log-reduction within 3 minutes" of natural biofilm on implant materials in laboratory tests, meaning 99.999% of bacteria killed. The CORDIS report describes "a holistic therapy concept to reliably treat periimplantitis" and says the company prepared its supply chain, distribution and service. No clinical outcome data have been published.
What the EIC Project Promised, and What CORDIS Shows
The project promised "the world's first and only highly effective plasma-based solution" for Europe's peri-implantitis patients. The report says the device was built for mass manufacturing and passed the required regulatory tests, and that the company "up-scaled". It does not report a CE certificate, a clinical result or a sale, and the company's own website says approval is still to come.
- Manufacturable deviceDeliveredBase station and applicators.
- Regulatory testsPassedPer CORDIS report.
- Market approvalPending"Countdown" in 2026.
- Clinical evidenceUnder way26-patient study from 2026.
What Has Happened Since the Award
The Money
The company's financial statements are filed in Germany but not freely displayed. Its public funding includes the EIC grant and an earlier German grant of €741,943 for the Dentalplas project, according to North Data. The capital increase shows new shares were issued by August 2025; the amount paid was not announced.
What cannot be checked
Whether AmbiJet holds a CE certificate, when it will go on sale, the company's revenue and losses, and who invested in 2025 are not public.
Why Europe Should Care
The EIC paid most of the cost of developing a new kind of treatment for a common dental complication. The device exists and, by the company's account, meets EU technical requirements. Patients cannot yet get it, and clinical evidence is only now being collected.
What the project promised
The first highly effective plasma treatment for peri-implantitis patients in Europe.
What the record shows
A manufacturable device and passed tests, market approval still pending, and a 26-patient study started in 2026.
The Verdict
Ready on paper, not yet in clinics
AmbiJet came out of the EIC project as a finished device that the company says met EU tests. A year later it is not on the market and its first clinical study is small and still recruiting.
Freiburger Medizintechnik has not been asked for comment for this article. It is based entirely on company statements, German register data, clinical registries and EU project data, linked throughout.
